The EU (Union) list of critical medicines enables EMA, HMA and the European Commission to work together to ensure they can take proactive measures to avoid medicine shortages.
This list contains human medicines whose continued supply is considered a priority in the EU. It helps healthcare systems function and avoid serious harm to patients.
EMA published the second version of this list on December 2024. Find it below:
Medicines on this list will be prioritised for EU-wide actions to strengthen their supply chains and minimise the risk of supply disruptions.
EMA also uses this list in the establishment of a product management database to support the standardisation of product information in the EU and in the European Economic Area (EEA).
The European medicines regulatory network published the first version of the list in December 2023. The network updated the list in 2024.
It includes innovative medicines and generic medicines for human use covering a wide range of therapeutic areas - such as vaccines and medicines for rare diseases.
The Union list results from the national competent authorities' review of 2,200 active substances groups and combinations, which account for 75% of the authorised medicinal products in the EU. The network drew these active substances from existing lists within the network, such as the list of main therapeutic groups and national lists of critical medicines.
A questions and answers document on the Union list is also available below:
EU Member States assign critical medicine status based on a methodology developed with input from key stakeholder groups. This includes patient and healthcare professionals organisations, and pharmaceutical industry associations.
A critical medicine is identified by combining two criteria:
A medicine also has to meet additional criteria to be included in the list, such a defined number of Member States that consider the medicine to be critical or the marketing status of the medicine.
The European medicines regulatory network will closely monitor the medicines on the Union list and implement measures to minimise the risk of supply disruptions.
It will do so via existing processes and structures, as defined in the mandate of EMA’s Medicines Shortages Single Point of Contact (SPOC) Working Party and its Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG).
Additional obligations for marketing authorisation holders and national competent authorities are further defined in the upcoming proposed EU pharmaceutical legislation.
The European Commission has analysed the vulnerabilities in the supply chain of selected critical medicines in the Union list. On July 2024, the Commission published the main findings for the first tranche of 11 critical medicines in a technical report.
On October 2023, the Commission published a communication on addressing critical shortages of medicines. This document lays out the plans for regulatory and industrial policy measures to address supply chain vulnerabilities.
The Commission may propose measures to address vulnerabilities and strengthen security of supply for critical medicines, including:
These measures will support the prevention and mitigation of shortages, and ensure appropriate and continued supply of critical medicines for patients and healthcare systems across the EU.
For more information, see:
Information helping marketing authorisation holders and national competent authorities to map their products in EMA's product management service (PMS) is available to registered users with full access to the Product Lifecycle Management portal (PLM):
This helps them report data on the supply and demand of medicines to the European Shortages Monitoring Platform. It is part of their mandatory reporting requirements and is meant to help prevent, detect and manage human medicine shortages.
Guidance on how to access the dynamic product reports that contain this information is also available on the PLM portal.
In February 2025, these reports replaced the list of products and pack sizes that EMA previously made available. This document was based on the first version of the Union list of critical medicines. The document is outdated but remains available below for information.
Mapping products in the PMS supports the implementation of standardised product information across the EU and EEA.